Monday, July 20, 2026

P1 · Therapeutic area intelligence

Immunology patent intelligence

Autoimmune, rheumatology, and immunology biologic patents — biosimilar entry timing signals.

Patents
11

Quick answer

11 US pharmaceutical patents in our index match Immunology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12246064

    Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11884731

    Vedolizumab for the treatment of fistulizing Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11622991

    Protocol for treatment of lupus nephritis

    AURINIA PHARMACEUTICALS INC. · Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 10286036

    Protocol for treatment of lupus nephritis

    AURINIA PHARMACEUTICALS INC. · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9687522

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 2017020867

    USE OF MASITINIB FOR THE TREATMENT OF CROHN'S DISEASE

    AB SCIENCE [FR] · Granted Thu Jan 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 9161935

    Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 8889661

    Treatment of lupus nephritis using laquinimod

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8759302

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 8598203

    Treatment of Crohn's disease with laquinimod

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Dec 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 8501766

    Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Immunology patents are indexed?

11 patents match our Immunology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.